CBO scores drug pricing reform as budget-neutral by Q1 2027

The Congressional Budget Office is expected to evaluate the reform’s fiscal impact as neutral or positive, reducing political opposition. This outcome will depend on finalized bill details and CBO’s scoring methodology.

Implied probability (Yes)

68%